Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMBER: Imlunestrant in ER+ Advanced Breast and Endometrial Cancers
NCT04188548Phase 1Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2019
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 1, open-label trial of imlunestrant in breast cancer and endometrial cancer (EC) (8 arms), sponsored by Eli Lilly and Company. Primary endpoint: Dose Limiting Toxicities at 4 weeks. Started Dec 2019; status: active, not recruiting.
02
Drugs
imlunestrant
03
Conditions
breast cancerendometrial cancer (EC)
Beyond the preview
Go deeper on NCT04188548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04188548.